GlassScriptPhysician profile
Stephen Dong
NPI 1265811582
$1,708.42
in general payments reported to CMS, 2019-2025
17 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $402 · 2021: $257 · 2022: $69.43 · 2023: $209 · 2024: $27.26 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $209 · Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $208.72 |
| Food and Beverage | $140.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $214.19 | 2019-2020 | |
| Intuitive Surgical, INC. | $208.72 | 2023 | Da Vinci Surgical System |
| Alexion Pharmaceuticals, INC. | $174.66 | 2019 | |
| Genzyme Corporation | $160.97 | 2021 | |
| Celgene Corporation | $141.45 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.69 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.33 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $112.57 | 2020-2021 | |
| Exelixis INC. | $99.67 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $69.43 | 2022 | |
| Genentech USA, INC. | $66.28 | 2019-2020 | |
| Incyte Corporation | $47.98 | 2021 | |
| Abbvie INC. | $45.51 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $36.82 | 2019 | |
| Pfizer INC. | $33.08 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $24.41 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $22.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Dong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.